-
Mashup Score: 7Home - The Wrong Question - Stop Asking "Did You Smoke?" - 2 day(s) ago
Stop asking the wrong question. Whether they smoked or never had a puff, all people with a lung cancer diagnosis deserve care and compassion.
Source: thewrongquestion.caCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 39Salvage percutaneous high-dose-rate brachyablation after stereotactic body radiation therapy for early-stage non-small cell lung cancer - 2 day(s) ago
Patients with primary tumor progression after stereotactic body radiation therapy (SBRT) for stage I non-small cell lung cancer (NSCLC) have a second chance at complete tumor eradication with salvage local therapies, including lung resection, repeat course of SBRT, and percutaneous ablative…
Source: www.termedia.plCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 21Perioperative Nivolumab in Resectable Lung Cancer | NEJM - 2 day(s) ago
Standard treatment with neoadjuvant nivolumab plus chemotherapy significantly improves outcomes in patients with resectable non–small-cell lung cancer (NSCLC). Perioperative treatment (i.e., neoadj…
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 46
Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 CheckMate -73L trial did not meet its primary endpoint of progression-free survival (PFS) in unresectable, locally advanced stage III non-small cell lung cancer (NSCLC). CheckMate -73L evaluated Opdivo® (nivolumab) with concurrent chemoradiotherapy (CCRT) followed by Opdivo plus Yervoy® (ipilimumab) versus CCRT followed by durvalumab in patients with unresectable stage III NSCLC. The observed adverse events of Opdivo with CCRT followed by Opdivo plus Yervoy were generally consistent with the known profiles of each component in the regimen. “Unfortunately, adding immunotherapy concurrently with definitive chemoradiation did not improve PFS outcomes in this setting,” said Joseph Fiore, vice president, global program lead, thoracic cancers, Bristol Myers Squibb. “There remains a critical need to improve long-term outcomes for these patients and we believe these results will help inform future drug development efforts in this
Source: news.bms.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 46
Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 CheckMate -73L trial did not meet its primary endpoint of progression-free survival (PFS) in unresectable, locally advanced stage III non-small cell lung cancer (NSCLC). CheckMate -73L evaluated Opdivo® (nivolumab) with concurrent chemoradiotherapy (CCRT) followed by Opdivo plus Yervoy® (ipilimumab) versus CCRT followed by durvalumab in patients with unresectable stage III NSCLC. The observed adverse events of Opdivo with CCRT followed by Opdivo plus Yervoy were generally consistent with the known profiles of each component in the regimen. “Unfortunately, adding immunotherapy concurrently with definitive chemoradiation did not improve PFS outcomes in this setting,” said Joseph Fiore, vice president, global program lead, thoracic cancers, Bristol Myers Squibb. “There remains a critical need to improve long-term outcomes for these patients and we believe these results will help inform future drug development efforts in this
Source: news.bms.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 46
Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 CheckMate -73L trial did not meet its primary endpoint of progression-free survival (PFS) in unresectable, locally advanced stage III non-small cell lung cancer (NSCLC). CheckMate -73L evaluated Opdivo® (nivolumab) with concurrent chemoradiotherapy (CCRT) followed by Opdivo plus Yervoy® (ipilimumab) versus CCRT followed by durvalumab in patients with unresectable stage III NSCLC. The observed adverse events of Opdivo with CCRT followed by Opdivo plus Yervoy were generally consistent with the known profiles of each component in the regimen. “Unfortunately, adding immunotherapy concurrently with definitive chemoradiation did not improve PFS outcomes in this setting,” said Joseph Fiore, vice president, global program lead, thoracic cancers, Bristol Myers Squibb. “There remains a critical need to improve long-term outcomes for these patients and we believe these results will help inform future drug development efforts in this
Source: news.bms.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1
Authors describe the science behind use of ADI in risk adjustment and present a five-point framework for considering ACO REACH and the HEBA, as well as future health equity policy.
Source: www.healthaffairs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1
The bill sailed through a vote in the UK parliament.
Source: www.iflscience.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 10How to Control Your Emotions During a Difficult Conversation - 1 month(s) ago
When you’re in the middle of a conflict, it’s common to automatically enter into a “fight or flight” mentality. But it’s possible to interrupt this response and clear a path towards entering into a more productive discussion. Start by taking a deep breath and focusing on your body. Repeat a mantra to yourself such as “This isn’t about me,” “This will pass,” or “This is about the business.” And try to distance yourself from the negative emotion you’re feeling by labeling it: “He is so wrong about that and it’s making me mad becomes I’m having the thought that my coworker is wrong, and I’m feeling anger.” And don’t forget the value of taking a break. The more time you give yourself to process your emotions, the less intense they are likely to be.
Source: hbr.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 20Shortage of thoracic surgeons in the United States: Implications for treatment and survival for stage I lung cancer patients - 1 month(s) ago
To evaluate whether there is a shortage of thoracic surgeons in the United States and whether any potential shortage is impacting lung cancer treatment and outcomes.
Source: www.jtcvs.orgCategories: General Medicine News, Hem/OncsTweet
"Did you smoke?" is the wrong question. Thank you. #lcsm #radonc https://t.co/lDaohRQK8X https://t.co/y11mzOD5rd